Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioInvent International AB ( (SE:BINV) ) has issued an announcement.
BioInvent International AB announced promising early data from its Phase 2a trial of BI-1206 in combination with rituximab and Calquence for the treatment of relapsed/refractory non-Hodgkin’s lymphoma (NHL). The trial showed an 80% overall response rate, with 47% of patients achieving complete responses and a favorable safety profile, suggesting the potential of this combination to overcome resistance to rituximab and provide a new therapeutic option for patients with limited alternatives.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK28.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a biotechnology company based in Lund, Sweden, focusing on the discovery and development of novel immunomodulatory antibodies for cancer immunotherapy. The company is particularly involved in creating treatments for CD20 expressing blood cancers, with a market focus on non-Hodgkin’s lymphoma (NHL).
YTD Price Performance: -25.06%
Average Trading Volume: 98,652
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK1.9B
See more data about BINV stock on TipRanks’ Stock Analysis page.